208 related articles for article (PubMed ID: 21839620)
21. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
Nimatoudis I; Zissis NP; Kogeorgos J; Theodoropoulou S; Vidalis A; Kaprinis G
Int Clin Psychopharmacol; 2004 Nov; 19(6):331-6. PubMed ID: 15486518
[TBL] [Abstract][Full Text] [Related]
22. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
[TBL] [Abstract][Full Text] [Related]
23. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis.
Stein DJ; Bruce Lydiard R; Herman BK; Mandel FS
Int Clin Psychopharmacol; 2009 May; 24(3):126-32. PubMed ID: 19352198
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Rickels K; Pollack MH; Sheehan DV; Haskins JT
Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.
Khan A; Joyce M; Atkinson S; Eggens I; Baldytcheva I; Eriksson H
J Clin Psychopharmacol; 2011 Aug; 31(4):418-28. PubMed ID: 21694613
[TBL] [Abstract][Full Text] [Related]
26. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of pregabalin in generalized anxiety disorder.
Feltner D; Wittchen HU; Kavoussi R; Brock J; Baldinetti F; Pande AC
Int Clin Psychopharmacol; 2008 Jan; 23(1):18-28. PubMed ID: 18090504
[TBL] [Abstract][Full Text] [Related]
29. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial.
Hadley SJ; Mandel FS; Schweizer E
J Psychopharmacol; 2012 Apr; 26(4):461-70. PubMed ID: 21693549
[TBL] [Abstract][Full Text] [Related]
30. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Feltner DE; Liu-Dumaw M; Schweizer E; Bielski R
Int Clin Psychopharmacol; 2011 Jul; 26(4):213-20. PubMed ID: 21368587
[TBL] [Abstract][Full Text] [Related]
32. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
Lydiard RB; Pitrosky B; Hackett D; White C
J Clin Psychiatry; 2004 Jun; 65(6):838-44. PubMed ID: 15291662
[TBL] [Abstract][Full Text] [Related]
33. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
Simon JS; Aguiar LM; Kunz NR; Lei D
J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
[TBL] [Abstract][Full Text] [Related]
34. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
35. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
37. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.
Montgomery SA; Sheehan DV; Meoni P; Haudiquet V; Hackett D
J Psychiatr Res; 2002; 36(4):209-17. PubMed ID: 12191625
[TBL] [Abstract][Full Text] [Related]
39. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
Rickels K; Etemad B; Rynn MA; Lohoff FW; Mandos LA; Gallop R
Psychother Psychosom; 2013; 82(6):363-71. PubMed ID: 24061331
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
